Clinical Trials
3 trialsNCT01283945 2024-07-25
Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
Servier
Phase 1/2 Completed
NCT02053636 2024-07-25
FINESSE
Servier
Phase 2 Completed
NCT03117101 2017-04-17
Study of the AL3810 in the Treatment of Advanced Solid Tumor
Haihe Biopharma Co., Ltd.
Phase 1 Completed